This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): loratadine
Description: Claritin (Loratadine) is an anti-histamine with selective H-1 receptor (H1R) histamine antagonist activity. Histamine, acting on H1-receptors, produces pruritis, vasodilatation, hypotension, flushing, headache, tachycardia, bronchoconstriction, increases vascular permeability, potentiates pain, and more.
Deal Structure: Claritin was originally developed by Schering-Plough.
In March 2009, Merck & Co and Schering-Plough announced that their Boards of Directors have unanimously approved a definitive merger agreement under which Merck and Schering-Plough will combine, under the name Merck, in a stock and cash transaction. Under the terms of the agreement, Schering-Plough shareholders will receive 0.5767 shares and $10.50 in cash for each share of Schering-Plough. Each Merck share will automatically become a share of the combined company. Merck & Co and Schering-Plough announced that their merger completed on November 3, 2009.
Bayer and Merck
In May 2014, Merck entered into a definitive agreement to sell its Merck Consumer Care (MCC) business to Bayer AG (BAYRY) for $14.2 billion. Under the terms of the agreement, Bayer AG will acquire Mercks existing OTC business, including the global trademark and prescription rights for Claritin and Afrin.
Additional information available to subscribers only: